Articles related to AGE-RELATED MACULAR DEGENERATION (AMD)

“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix

More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book.

“This genetic overlap suggests that there may be shared biological pathways or metabolic mechanisms connecting the preference for instant coffee with the risk of developing dry AMD.”

A formulation of over-the-counter antioxidant supplements reduced the progression of geographic atrophy, an advanced form of dry age-related macular degeneration, by 55% over three years compared to placebo.

The identification of subretinal drusenoid deposits (SDDs), which carry the highest risk for AMD progression, is a critical aspect of early diagnosis.

When atypical AMD is suspected, additional multimodal imaging and a more detailed medical history are required to establish the correct diagnosis. The medical history, clinical examination, and retinal imaging findings of a 69-year-old White man with a long-standing medical history of schizophrenia, bilateral visual decline, nyctalopia, and blurred vision were sufficient evidence for the doctors to establish a presumed diagnosis of thioridazine retinal toxicity. Although it is a rare diagnosis due to the introduction of newer medications, patients with an underlying psychiatric history and atypical retinal findings on examination may have been or are currently taking the culprit psychotropic medication.